Promising drug shows hope for rare skin condition
NCT ID NCT06444399
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called deucravacitinib in 7 adults with pityriasis rubra pilaris, a rare skin disease that causes red, scaly patches. The goal was to see if the drug safely improves skin symptoms and itching over 24 weeks. Researchers also looked for unique markers in the skin to predict who might respond best.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITYRIASIS RUBRA PILARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.